Distribution of 68Ga-HA-DOTATATE and 68Ga-DOTATATE in 343 Patients: Not the Same after All
#1700
Introduction: For the detection of neuroendocrine tumors, 68Ga-DOTATATE was developed but its use is restricted. This led to the development of 68Ga-HA-DOTATATE. In the literature, they are described as having comparable distributions.
Aim(s): To retrospectively evaluate the distribution of 68Ga-DOTATATE and 68Ga-HA-DOTATATE in an independent patient population.
Materials and methods: All 68Ga-DOTATATE and 68Ga-HA-DOTATATE PET scans between 11-2011 and 04-2016 that were acquired 45±10 minutes post-injection were evaluated. The SUVmax and SUVmean was determined for the liver, spleen, kidney, aortic arch, pituitary-, adrenal-, parotid-, and thyroid glands. Independent sample T-testing was used to determine the difference between 68Ga-DOTATATE and 68Ga-HA-DOTATATE in each organ.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Aalbersberg E, Stokkel M,
Keywords: HA-DOTATATE,
To read the full abstract, please log into your ENETS Member account.